Narrow Therapeutic Index Drugs: Why Stricter Bioequivalence Rules Matter for Patient Safety
Narrow therapeutic index drugs require stricter bioequivalence rules to prevent dangerous side effects. Learn how the FDA, EMA, and Health Canada ensure generic versions are safe - and why these rules matter for patient outcomes.
CONTINUE